Potassium permanganate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Potassium permanganate
Accession Number
DB13831
Description
Not Available
Type
Small Molecule
Groups
Experimental, Investigational
Structure
Thumb
Weight
Average: 158.032
Monoisotopic: 157.881409
Chemical Formula
KMnO4
Synonyms
Not Available
External IDs
  • NSC-146182

Pharmacology

Indication
Not Available
Associated Therapies
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololPotassium permanganate may increase the hyperkalemic activities of Acebutolol.
AceclofenacPotassium permanganate may increase the hyperkalemic activities of Aceclofenac.
AcemetacinPotassium permanganate may increase the hyperkalemic activities of Acemetacin.
Acetylsalicylic acidPotassium permanganate may increase the hyperkalemic activities of Acetylsalicylic acid.
AlclofenacPotassium permanganate may increase the hyperkalemic activities of Alclofenac.
AliskirenPotassium permanganate may increase the hyperkalemic activities of Aliskiren.
AmilorideThe risk or severity of hyperkalemia can be increased when Potassium permanganate is combined with Amiloride.
AminophenazonePotassium permanganate may increase the hyperkalemic activities of Aminophenazone.
AmiodaronePotassium permanganate may increase the hyperkalemic activities of Amiodarone.
AmlodipinePotassium permanganate may increase the hyperkalemic activities of Amlodipine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

ATC Codes
V03AB18 — Potassium permanganateD08AX06 — Potassium permanganate
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of inorganic compounds known as alkali metal permanganates. These are inorganic compounds in which the largest oxoanion is permanganate, and in which the heaviest atom not in an oxoanion is an alkali metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Alkali metal oxoanionic compounds
Sub Class
Alkali metal permanganates
Direct Parent
Alkali metal permanganates
Alternative Parents
Inorganic salts / Inorganic oxides
Substituents
Alkali metal permanganate / Inorganic oxide / Inorganic salt
Molecular Framework
Not Available
External Descriptors
Not Available

Chemical Identifiers

UNII
00OT1QX5U4
CAS number
7722-64-7
InChI Key
VZJVWSHVAAUDKD-UHFFFAOYSA-N
InChI
InChI=1S/K.Mn.4O/q+1;;;;;-1
IUPAC Name
potassium manganesoylolate
SMILES
[K+].[O-][Mn](=O)(=O)=O

References

General References
Not Available
ChemSpider
22810
RxNav
8604
ChEMBL
CHEMBL3833305
Wikipedia
Potassium_permanganate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionHealthcare Associated Pneumonia / Healthcare-Associated Pneumonia / Nosocomial Pneumonia / Pneumonia, Aspiration / Ventilator-associated Bacterial Pneumonia / Ventilator-Associated Pneumonia (VAP)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Powder
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-2.3ChemAxon
pKa (Strongest Acidic)-7ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area74.27 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity5.77 m3·mol-1ChemAxon
Polarizability6.08 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on June 23, 2017 14:49 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates